Stanley R. Riddell
Adoptive T-cell therapy pioneer whose defined-composition CAR-T work led to lisocabtagene maraleucel.
Immunologist who pioneered antigen-specific T-cell transfer for viral infections after transplant and later CD19 CAR-T with defined CD4:CD8 ratios, the basis of Juno Therapeutics and Breyanzi. Works on CAR design and solid-tumour targets such as ROR1.
| Title | Journal | Year |
|---|---|---|
| CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients | Journal of Clinical Investigation | 2016 |
| Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones | Science | 1992 |
Pages like this
not linked directly; found by shared links- TrialTRANSCEND CLL 004
Shares Lisocabtagene maraleucel, CD19, Chronic lymphocytic leukaemia, CAR-T cell therapy.
- PersonJae H. Park
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- PersonCarl H. June
Shares CD19, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- TrialwaveLINE-003
Shares ROR1, Diffuse large B-cell lymphoma.
- TrialFELIX
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares CD19, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaHospital-made CAR-T under one shared regulatory master file
Shares CD19, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- PersonDavid L. Porter
Shares CD19, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, CAR-T cell therapy.